Novavax secures a non-exclusive licensing deal with Pfizer, validating Matrix-M's platform value and shifting NVAX toward a technology provider model. NVAX receives $30M upfront, a potential $500M in ...
All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. Having personally tested ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results